Q1 Earnings Estimate for MBOT Issued By HC Wainwright

Microbot Medical Inc. (NASDAQ:MBOT) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Microbot Medical in a research note issued on Tuesday, June 10th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will post earnings of ($0.07) per share for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical’s Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.23) EPS.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.07.

Microbot Medical Price Performance

MBOT stock opened at $2.50 on Wednesday. The stock has a market cap of $90.95 million, a PE ratio of -3.12 and a beta of 1.14. Microbot Medical has a one year low of $0.82 and a one year high of $3.38. The firm has a 50 day simple moving average of $2.42 and a two-hundred day simple moving average of $1.84.

Institutional Investors Weigh In On Microbot Medical

Hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Microbot Medical during the first quarter valued at approximately $42,000. Goldman Sachs Group Inc. bought a new position in shares of Microbot Medical during the first quarter valued at about $57,000. Renaissance Technologies LLC purchased a new stake in shares of Microbot Medical during the fourth quarter worth about $118,000. Finally, Geode Capital Management LLC grew its stake in shares of Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 10,442 shares during the last quarter. Institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.